- Home
- NCPL vs ISPC Comparison
NCPL vs ISPC Comparison
Compare NCPL & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCPL | ISPC |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NCPL | ISPC |
|---|---|---|
| Price | $0.42 | $5.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 159.4K | ★ 23.1M |
| Earning Date | 03-19-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,928,998.00 |
| Revenue This Year | $739.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.31 | $0.10 |
| 52 Week High | $8.75 | $6.77 |
Technical Indicators
Market Signals| Indicator | NCPL | ISPC |
|---|---|---|
| Relative Strength Index (RSI) | 54.68 | 76.40 |
| Support Level | $0.36 | $0.37 |
| Resistance Level | $0.47 | $6.77 |
| Average True Range (ATR) | 0.03 | 0.66 |
| MACD | 0.00 | 0.26 |
| Stochastic Oscillator | 89.29 | 76.11 |
Price Performance
Historical ComparisonAbout NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.